myoscience to Present at 2012 Canaccord Genuity Medical Technology Forum

REDWOOD CITY, Calif., Nov. 27, 2012 (GLOBE NEWSWIRE) -- myoscience, inc., the developer of Focused Cold Therapy for the treatment of peripheral nerve conditions, announced that President & CEO, Clint Carnell, will be presenting at the Canaccord Genuity Medical Technology and Diagnostics Forum to be held on Tuesday, December 4, 2012 at the Le Parker Meridien in New York, NY.

Clint Carnell will speak at 10:00am Eastern Time about the upcoming 2013 European Union launch of the company's first aesthetics product for the treatment of wrinkles. Mr. Carnell will also provide an overview of Focused Cold Therapy and the opportunities in therapeutics such as pain and various movement disorders.

The presentation will be webcast live and may be accessed by visiting the myoscience website at www.myoscience.com.

About myoscience

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the pre-eminent treatment for nerves. Focused Cold Therapy is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.

The myoscience logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13581

CONTACT: Clint Carnell President & CEO 650-421-0600 ccarnell@myoscience.com

Source: myoscience

More From Press Releases